| Type | Title | Date Released | |
|---|---|---|---|
8-K | 60 Degrees Pharmaceuticals Enters Warrant Inducement Agreements to Raise Gross Proceeds of $526,042.80 | ||
8-K | 60 Degrees Pharmaceuticals Announces Positive Clinical and Molecular Results in Expanded Access Babesiosis Study | ||
8-K | 60 Degrees Pharmaceuticals Presents Tafenoquine Progress for Babesiosis at 2026 ILADS Conference | ||
8-K | 60 Degrees Pharmaceuticals Provides Tafenoquine Babesiosis Study Update and Milestones | ||
8-K | 60 Degrees Pharmaceuticals Submits Statement of Interest for FDA Commissioner’s National Priority Voucher for ARAKODA to Treat Babesiosis | ||
8-K | 60 Degrees Pharmaceuticals Highlights ARAKODA® Platform Expansion into Babesiosis at H.C. Wainwright Presentation | ||
EFFECT | Form EFFECT | ||
DEL AM | Form DEL AM | ||
S-3 | SHARE RESALE REGISTRATION | ||
10-Q | Form 10-Q | ||
8-K | 60 Degrees Pharmaceuticals, Inc. Announces Results of 2026 Annual Stockholders Meeting | ||
SCHEDULE 13G | Lind Global Fund III LP (Filed by) |
